‘Phar­ma Bro’ Mar­tin Shkre­li's com­pa­nies file for bank­rupt­cy

The com­pa­ny found­ed by Mar­tin Shkre­li, the “Phar­ma Bro” known for hik­ing the price of an old drug by 4,000%, has filed for Chap­ter 11 bank­rupt­cy in Delaware.

Vy­era Phar­ma­ceu­ti­cals, which is the re­brand­ed ver­sion of Shkre­li’s Tur­ing Phar­ma­ceu­ti­cals, its par­ent com­pa­ny Phoenixus AG and four oth­er com­pa­nies filed for Chap­ter 11 pro­tec­tion on Wednes­day, ac­cord­ing to doc­u­ments from the US Bank­rupt­cy Court for the Dis­trict of Delaware. The case fil­ing for Vy­era states that the phar­ma plans to have a sale or liq­ui­da­tion of the “liq­ui­dat­ing debtors” and for Phoenixus to be pre­served.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN